GSK Bepirovirsen Wins FDA Priority Review Breakthrough Status
LONDON, United Kingdom, April 28, 2026 GSK has announced that its investigational antisense oligonucleotide therapy bepirovirsen has been accepted...
Liver Disease
Advertisement
Aligos-Amoytop $445M HBV Licensing Deal Expands Access
SOUTH SAN FRANCISCO, Calif., April 16, 2026 Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop...
Aligos Therapeutics Gains Fast Track for HBV Drug
SOUTH SAN FRANCISCO, Calif., April 14, 2026 Aligos Therapeutics, Inc. has announced encouraging progress in its Phase 2 B-SUPREME...
GSK Bepirovirsen Wins EMA Review for Hepatitis B Drug
London, UK | March 27, 2026 EMA Accepts First-in-Class Hepatitis B Therapy for Review GSK has announced that the...
Tangram Advances TGM-312 With Phase 1/2 CTA Submission
LONDON — November 26, 2025. Tangram Therapeutics has submitted a Clinical Trial Application (CTA) to the UK Medicines and...
Advertisements
PDS Biotechnology Presents Strong Immunotherapy and Translational Data Demonstrating Broad Immune Activation at SITC 2025
Princeton, New Jersey, November 10, 2025 — PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company developing next-generation immunotherapies for cancer...
Rivus Pharmaceuticals Reports Positive Phase 2 Results for HU6 in MASH Patients
CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., November 7, 2025 — Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pioneering...
Roche Completes Acquisition of 89bio in Strategic Biotech Expansion
Basel, Switzerland – October 30, 2025 — Roche Holding AG (SIX: RO, ROG; OTCQX: RHHBY) has successfully completed its...
Advertisement
